Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing

被引:73
|
作者
Xiao, Wenming [1 ]
Ren, Luyao [2 ,3 ]
Chen, Zhong [4 ]
Fang, Li Tai [5 ]
Zhao, Yongmei [6 ]
Lack, Justin [6 ]
Guan, Meijian [7 ]
Zhu, Bin [8 ]
Jaeger, Erich [9 ]
Kerrigan, Liz [10 ]
Blomquist, Thomas M.
Hung, Tiffany [13 ]
Sultan, Marc [14 ]
Idler, Kenneth [15 ]
Lu, Charles [15 ]
Scherer, Andreas [16 ,17 ]
Kusko, Rebecca [18 ]
Moos, Malcolm [19 ]
Xiao, Chunlin [20 ]
Sherry, Stephen T. [20 ]
Abaan, Ogan D. [9 ,21 ]
Chen, Wanqiu [4 ]
Chen, Xin [4 ]
Nordlund, Jessica [17 ,22 ]
Liljedahl, Ulrika [17 ,23 ]
Maestro, Roberta [17 ,23 ]
Polano, Maurizio [17 ,23 ]
Drabek, Jiri [17 ,24 ]
Vojta, Petr [17 ,24 ]
Koks, Sulev [17 ,25 ,26 ]
Reimann, Ene [17 ,27 ]
Madala, Bindu Swapna [28 ]
Mercer, Timothy [28 ]
Miller, Chris [15 ]
Jacob, Howard [15 ]
Truong, Tiffany [9 ]
Moshrefi, Ali [9 ]
Natarajan, Aparna [9 ]
Granat, Ana [9 ]
Schroth, Gary P. [9 ]
Kalamegham, Rasika [13 ]
Peters, Eric [13 ]
Petitjean, Virginie [14 ]
Walton, Ashley [6 ]
Shen, Tsai-Wei [6 ]
Talsania, Keyur [6 ]
Vera, Cristobal Juan [6 ]
Langenbach, Kurt [10 ]
de Mars, Maryellen [10 ]
Hipp, Jennifer A. [11 ,12 ]
机构
[1] US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA
[2] Fudan Univ, Sch Life Sci, Human Phenome Inst, State Key Lab Genet Engn, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[4] Loma Linda Univ, Sch Med, Ctr Genom, Loma Linda, CA 92350 USA
[5] Roche Sequencing Solut Inc, Bioinformat Res & Early Dev, Belmont, CA USA
[6] Frederick Natl Lab Canc Res, Biomed Informat & Data Sci Directorate, Adv Biomed & Computat Sci, Frederick, MD USA
[7] SAS Inst Inc, Cary, NC USA
[8] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA
[9] Illumina Inc, Foster City, CA USA
[10] ATCC, Manassas, VA USA
[11] Univ Toledo, Med Ctr, Dept Med, Toledo, OH USA
[12] Univ Toledo, Med Ctr, Dept Pathol, Toledo, OH USA
[13] Genentech Inc, San Francisco, CA 94080 USA
[14] Novartis Inst Biomed Res, Biomarker Dev, Basel, Switzerland
[15] AbbVie, Genom Res Ctr, Computat Genom, N Chicago, IL 60064 USA
[16] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland
[17] European Infrastruct Translat Med, Amsterdam, Netherlands
[18] Immuneering Corp, Cambridge, MA USA
[19] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA
[20] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bldg 10, Bethesda, MD 20892 USA
[21] Seven Bridges Genom Inc, Cambridge, MA USA
[22] Uppsala Univ, Dept Med Sci, Mol Med & Sci Life Lab, Uppsala, Sweden
[23] NCI, Ctr Riferimento Oncol Aviano, IRCCS, Unit Oncogenet & Funct Oncogen, Aviano, Italy
[24] Palacky Univ Olomouc, Fac Med & Dent, IMTM, Olomouc, Czech Republic
[25] Perron Inst Neurol & Translat Sci, Perth, WA, Australia
[26] Murdoch Univ, Ctr Mol Med & Innovat Therapeut, Perth, WA, Australia
[27] Univ Tartu, Estonian Genome Ctr, Inst Genom, Tartu, Estonia
[28] Kinghorn Canc Ctr, Garvan Inst Med Res, Darlinghurst, NSW, Australia
[29] Natl Inst Metrol, Beijing, Peoples R China
[30] Frederick Natl Lab Canc Res, Canc Res Technol Program, Sequencing Facil, Frederick, MD USA
[31] Ctr Canc Res, Off Sci & Technol Resources, CCR Collaborat Bioinformat Resource, Bethesda, MD USA
[32] NCI, Computat Genom & Bioinformat Branch, Ctr Biomed Informat & Informat Technol, Rockville, MD USA
[33] Digicon, Mclean, VA USA
[34] Virginia Polytech Inst & State Univ, Dept Biol Sci, Blacksburg, VA 24061 USA
[35] Q2 Solut EA Genom, Morrisville, NC USA
[36] NIEHS, Integrat Bioinformat, Durham, NC USA
[37] NHLBI, Bioinformat & Computat Biol Core, NIH, Bldg 10, Bethesda, MD 20892 USA
[38] Sentieon Inc, Mountain View, CA USA
[39] NIH, Ctr Informat Technol, Bldg 10, Bethesda, MD 20892 USA
[40] AstraZeneca, Gaithersburg, MD USA
[41] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA
[42] Weill Cornell Med, Dept Physiol & Biophys, New York, NY USA
[43] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[44] US FDA, Off Chief Scientist, Off Commissioner, Silver Spring, MD USA
[45] NCI, Lymphoid Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院; 中国国家自然科学基金;
关键词
SOMATIC POINT MUTATIONS; CLINICAL VALIDATION; READ ALIGNMENT; QUALITY; SAMPLES; DNA;
D O I
10.1038/s41587-021-00994-5
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Recommendations are given on optimal read coverage and selection of calling algorithm to maximize the reproducibility of cancer mutation detection in whole-genome or whole-exome sequencing. Clinical applications of precision oncology require accurate tests that can distinguish true cancer-specific mutations from errors introduced at each step of next-generation sequencing (NGS). To date, no bulk sequencing study has addressed the effects of cross-site reproducibility, nor the biological, technical and computational factors that influence variant identification. Here we report a systematic interrogation of somatic mutations in paired tumor-normal cell lines to identify factors affecting detection reproducibility and accuracy at six different centers. Using whole-genome sequencing (WGS) and whole-exome sequencing (WES), we evaluated the reproducibility of different sample types with varying input amount and tumor purity, and multiple library construction protocols, followed by processing with nine bioinformatics pipelines. We found that read coverage and callers affected both WGS and WES reproducibility, but WES performance was influenced by insert fragment size, genomic copy content and the global imbalance score (GIV; G > T/C > A). Finally, taking into account library preparation protocol, tumor content, read coverage and bioinformatics processes concomitantly, we recommend actionable practices to improve the reproducibility and accuracy of NGS experiments for cancer mutation detection.
引用
收藏
页码:1141 / +
页数:27
相关论文
共 50 条
  • [1] Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing
    Wenming Xiao
    Luyao Ren
    Zhong Chen
    Li Tai Fang
    Yongmei Zhao
    Justin Lack
    Meijian Guan
    Bin Zhu
    Erich Jaeger
    Liz Kerrigan
    Thomas M. Blomquist
    Tiffany Hung
    Marc Sultan
    Kenneth Idler
    Charles Lu
    Andreas Scherer
    Rebecca Kusko
    Malcolm Moos
    Chunlin Xiao
    Stephen T. Sherry
    Ogan D. Abaan
    Wanqiu Chen
    Xin Chen
    Jessica Nordlund
    Ulrika Liljedahl
    Roberta Maestro
    Maurizio Polano
    Jiri Drabek
    Petr Vojta
    Sulev Kõks
    Ene Reimann
    Bindu Swapna Madala
    Timothy Mercer
    Chris Miller
    Howard Jacob
    Tiffany Truong
    Ali Moshrefi
    Aparna Natarajan
    Ana Granat
    Gary P. Schroth
    Rasika Kalamegham
    Eric Peters
    Virginie Petitjean
    Ashley Walton
    Tsai-Wei Shen
    Keyur Talsania
    Cristobal Juan Vera
    Kurt Langenbach
    Maryellen de Mars
    Jennifer A. Hipp
    [J]. Nature Biotechnology, 2021, 39 : 1141 - 1150
  • [2] Achieving reproducibility and accuracy in cancer mutation detection with whole-genome and whole-exome sequencing
    Xiao, Wenming
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [3] Whole-genome and whole-exome sequencing in neurological diseases
    Foo, Jia-Nee
    Liu, Jian-Jun
    Tan, Eng-King
    [J]. NATURE REVIEWS NEUROLOGY, 2012, 8 (09) : 508 - 517
  • [4] Whole-genome and whole-exome sequencing in neurological diseases
    Jia-Nee Foo
    Jian-Jun Liu
    Eng-King Tan
    [J]. Nature Reviews Neurology, 2012, 8 : 508 - 517
  • [5] Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape
    Ganatra, Hetvi
    Tan, Joecelyn Kirani
    Simmons, Ana
    Bigogno, Carola Maria
    Khurana, Vatsala
    Ghose, Aruni
    Ghosh, Adheesh
    Mahajan, Ishika
    Boussios, Stergios
    Maniam, Akash
    Ayodele, Olubukola
    [J]. BREAST CANCER, 2024,
  • [6] Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants
    Belkadi, Aziz
    Bolze, Alexandre
    Itan, Yuval
    Cobat, Aurelie
    Vincent, Quentin B.
    Antipenko, Alexander
    Shang, Lei
    Boisson, Bertrand
    Casanova, Jean-Laurent
    Abel, Laurent
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (17) : 5473 - 5478
  • [7] Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels
    Ramarao-Milne, P.
    Kondrashova, O.
    Patch, A. -M.
    Nones, K.
    Koufariotis, L. T.
    Newell, F.
    Addala, V.
    Lakis, V.
    Holmes, O.
    Leonard, C.
    Wood, S.
    Xu, Q.
    Mukhopadhyay, P.
    Naeini, M. M.
    Steinfort, D.
    Williamson, J. P.
    Bint, M.
    Pahoff, C.
    Nguyen, P. T.
    Twaddell, S.
    Arnold, D.
    Grainge, C.
    Basirzadeh, F.
    Fielding, D.
    Dalley, A. J.
    Chittoory, H.
    Simpson, P. T.
    Aoude, L. G.
    Bonazzi, V. F.
    Patel, K.
    Barbour, A. P.
    Fennell, D. A.
    Robinson, B. W.
    Creaney, J.
    Hollway, G.
    Pearson, J. V.
    Waddell, N.
    [J]. ESMO OPEN, 2022, 7 (04)
  • [8] Advantages and Perils of Clinical Whole-Exome and Whole-Genome Sequencing in Cardiomyopathy
    Francesco Mazzarotto
    Iacopo Olivotto
    Roddy Walsh
    [J]. Cardiovascular Drugs and Therapy, 2020, 34 : 241 - 253
  • [9] Whole-Genome and Whole-Exome Sequencing in Hereditary Cancer Impact on Genetic Testing and Counseling
    O'Daniel, Julianne M.
    Lee, Kristy
    [J]. CANCER JOURNAL, 2012, 18 (04): : 287 - 292
  • [10] Advantages and Perils of Clinical Whole-Exome and Whole-Genome Sequencing in Cardiomyopathy
    Mazzarotto, Francesco
    Olivotto, Iacopo
    Walsh, Roddy
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2020, 34 (02) : 241 - 253